Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Exclusion Criteria

• •1. Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
• •2. Gastrointestinal disease or gastrointestinal surgery
• •3. History of significant hypersensitivity reaction of amlodipine, candesartan, calcium channel blocker, angiotensin II receptor blocker or other drugs
• •4. Galactose intolerance
• •5. Sitting systolic blood pressure ≥ 140 mmHg or\< 90 mmHg, sitting diastolic blood pressure ≥ 95 mmHg or \< 60 mmHg, pulse ≥ 100 beats per minute
• •6. Aspartate aminotransferase, Alanine aminotransferase, Total bilirubin \> 2 x upper limit of normal range
• •7. Serum Creatinine \> upper limit of normal range
• •8. Drug abuse
• •9. Subject treated metabolizing enzyme inducers or inhibitors within 1 month
• •10. Subject treated ethical the counter or herbal medicine within 2 weeks, over-the-counter or vitamin within 1 week
• •11. Subject treated Investigational product(include Bioequivalence test) within 3 months
• •12. Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
• •13. Continuously taking Alcohol \> 21 units/week
• •14. Cigarette \> 10 cigarettes/day
• •15. Subjects with planning of dental treatment or any surgery
• •16. Another clinical condition in judgement of investigator